CEO Andrew Obenshain was paid $3,049,181 in fiscal year 2023, ↑ up 68.0% from fiscal year 2022 (SEC filing 0001293971-24-000049 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$3,049,181 ↑ Andrew Obenshain total, FY2023 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Andrew Obenshain | $681,657 | $0 | $863,590 | $1,142,440 | $348,024 | $0 | $13,470 | $3,049,181 |
| Chief Executive Officer | ||||||||
| Richard Colvin | 489,808 | 0 | 281,050 | 371,800 | 187,425 | 0 | 14,170 | 1,344,253 |
| Chief Medical Officer | ||||||||
| Thomas Klima | 479,615 | 0 | 281,050 | 371,800 | 183,600 | 0 | 13,470 | 1,329,535 |
| Chief Commercial and Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Andrew Obenshain | $3,049,181 | $1,814,700 | — | ↑ +1,234,481 |
| Richard Colvin | 1,344,253 | 1,364,776 | — | ↓ −20,523 |
| Thomas Klima | 1,329,535 | 1,247,251 | — | ↑ +82,284 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read bluebird bio's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper BLUE reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses BLUE in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named BLUE in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2023 total |
|---|---|---|
| Charlotte Jones-Burton | Independent Director | $146,406 |
| Elisabeth Leiderman | Independent Director | $167,906 |
| John O. Agwunobi | Independent Director | $160,906 |
| Mark Vachon | Chair of the Board | $200,906 |
| Michael Cloonan | Independent Director | — |
| Najoh Tita-Reid | Independent Director | $153,906 |
| Nick Leschly | Independent Director | $96,406 |
| Richard Paulson | Independent Director | $65,238 |
Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Andrew Obenshain | Director | 2025-01-06 | D | 140 | $9 | $1,294 | Common | Form 4 ↗ |
| Richard Colvin | Chief Medical Officer | 2025-01-06 | D | 19 | 9 | 176 | Common | Form 4 ↗ |
| Joseph Vittiglio | Chief Business & Legal Officer | 2025-02-03 | D | 238 | 7 | 1,759 | Common | Form 4 ↗ |
| Richard Colvin | Chief Medical Officer | 2025-02-03 | D | 64 | 7 | 473 | Common | Form 4 ↗ |
| Andrew Obenshain | Director | 2025-02-03 | D | 86 | 7 | 636 | Common | Form 4 ↗ |
| Thomas Klima | See Remarks | 2025-02-03 | D | 122 | 7 | 902 | Common | Form 4 ↗ |
| Andrew Obenshain | Director | 2025-02-10 | A | 763 | 0 | 0 | Common | Form 4 ↗ |
| Richard Colvin | Chief Medical Officer | 2025-03-03 | D | 584 | 4 | 2,289 | Common | Form 4 ↗ |
| Andrew Obenshain | Director | 2025-03-03 | D | 921 | 4 | 3,610 | Common | Form 4 ↗ |
| Thomas Klima | See Remarks | 2025-03-03 | D | 500 | 4 | 1,960 | Common | Form 4 ↗ |
| Nick Leschly | Director | 2025-05-30 | D | 6,150 | — | — | Common | Form 4 ↗ |
| Thomas Klima | See Remarks | 2025-05-30 | D | 3,414 | — | — | Common | Form 4 ↗ |
| Najoh Tita-Reid | Director | 2025-05-30 | D | 1,163 | — | — | Common | Form 4 ↗ |
| Mark Vachon | Director | 2025-05-30 | D | 1,252 | — | — | Common | Form 4 ↗ |
| Charlotte Jones-Burton | Director | 2025-05-30 | D | 928 | — | — | Common | Form 4 ↗ |
| Elisabeth Leiderman | Director | 2025-05-30 | D | 1,112 | — | — | Common | Form 4 ↗ |
| Richard Colvin | Chief Medical Officer | 2025-05-30 | D | 3,552 | — | — | Common | Form 4 ↗ |
| Richard Paulson | Director | 2025-05-30 | D | 155 | — | — | Common | Form 4 ↗ |
| Joseph Vittiglio | Chief Business & Legal Officer | 2025-05-30 | D | 1,143 | — | — | Common | Form 4 ↗ |
| Andrew Obenshain | Director | 2025-05-30 | D | 9,027 | — | — | Common | Form 4 ↗ |
| Nick Leschly | Director | 2025-05-30 | D | 2,284 | — | — | Common | Form 4 ↗ |
| Nick Leschly | Director | 2025-05-30 | D | 14,416 | — | — | Common | Form 4 ↗ |
| John O. Agwunobi | Director | 2025-05-30 | D | 1,323 | — | — | Common | Form 4 ↗ |
| O. James Sterling | Chief Financial Officer | 2025-06-02 | D | 5,000 | — | — | Common | Form 4 ↗ |
| Richard Colvin | Chief Medical Officer | 2025-06-02 | A | 2,500 | — | — | Common | Form 4 ↗ |
| Joseph Vittiglio | Chief Business & Legal Officer | 2025-06-02 | A | 2,500 | — | — | Common | Form 4 ↗ |
| Thomas Klima | See Remarks | 2025-06-02 | D | 2,500 | — | — | Common | Form 4 ↗ |
| Thomas Klima | See Remarks | 2025-06-02 | A | 2,500 | — | — | Common | Form 4 ↗ |
| Andrew Obenshain | Director | 2025-06-02 | A | 14,820 | — | — | Common | Form 4 ↗ |
| O. James Sterling | Chief Financial Officer | 2025-06-02 | D | 2,500 | — | — | Common | Form 4 ↗ |
| Thomas Klima | See Remarks | 2025-06-02 | D | 4,464 | — | — | Common | Form 4 ↗ |
| Mark Vachon | Director | 2025-06-02 | D | 1,245 | — | — | Common | Form 4 ↗ |
| John O. Agwunobi | Director | 2025-06-02 | D | 1,245 | — | — | Common | Form 4 ↗ |
| Joseph Vittiglio | Chief Business & Legal Officer | 2025-06-02 | D | 2,500 | — | — | Common | Form 4 ↗ |
| Joseph Vittiglio | Chief Business & Legal Officer | 2025-06-02 | D | 3,125 | — | — | Common | Form 4 ↗ |
| Michael Cloonan | Director | 2025-06-02 | D | 1,867 | — | — | Common | Form 4 ↗ |
| O. James Sterling | Chief Financial Officer | 2025-06-02 | A | 2,500 | — | — | Common | Form 4 ↗ |
| Elisabeth Leiderman | Director | 2025-06-02 | D | 1,245 | — | — | Common | Form 4 ↗ |
| Najoh Tita-Reid | Director | 2025-06-02 | D | 1,245 | — | — | Common | Form 4 ↗ |
| Charlotte Jones-Burton | Director | 2025-06-02 | D | 1,245 | — | — | Common | Form 4 ↗ |
| Andrew Obenshain | Director | 2025-06-02 | D | 14,820 | — | — | Common | Form 4 ↗ |
| Andrew Obenshain | Director | 2025-06-02 | D | 9,300 | — | — | Common | Form 4 ↗ |
| Richard Colvin | Chief Medical Officer | 2025-06-02 | D | 2,500 | — | — | Common | Form 4 ↗ |
| Richard Paulson | Director | 2025-06-02 | D | 1,323 | — | — | Common | Form 4 ↗ |
| Richard Colvin | Chief Medical Officer | 2025-06-02 | D | 4,166 | — | — | Common | Form 4 ↗ |
| Nick Leschly | Director | 2025-06-02 | D | 1,245 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Andrew Obenshain | PRSU | — | — | — | — | — | $863,590 |
| Thomas Klima | Option | — | — | — | — | — | 371,800 |
| Andrew Obenshain | Option | — | — | — | — | — | 1,142,440 |
| Richard Colvin | Option | — | — | — | — | — | 371,800 |
| Thomas Klima | PRSU | — | — | — | — | — | 281,050 |
| Richard Colvin | PRSU | — | — | — | — | — | 281,050 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Andrew Obenshain | $0 | $0 | $1,142,440 | 0.0% |
| Thomas Klima | 0 | 0 | 371,800 | 0.0% |
| Richard Colvin | 0 | 0 | 371,800 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Richard Colvin | RSU | 55,000 | — | $75,900 |
| Thomas Klima | RSU | 55,000 | — | 75,900 |
| Andrew Obenshain | RSU | 15,059 | — | 20,781 |
| Richard Colvin | Option | 43,750 | 6.35 | — |
| Andrew Obenshain | RSU | 27,000 | — | 37,260 |
| Andrew Obenshain | RSU | 100,387 | — | 138,534 |
| Thomas Klima | RSU | 18,750 | — | 25,875 |
| Richard Colvin | RSU | 10,039 | — | 13,854 |
| Andrew Obenshain | RSU | 862 | — | 1,190 |
| Richard Colvin | RSU | 555 | — | 766 |
| Andrew Obenshain | RSU | 101,400 | — | 139,932 |
| Richard Colvin | RSU | 22,500 | — | 31,050 |
| Andrew Obenshain | RSU | 2,585 | — | 3,567 |
| Richard Colvin | RSU | 2,009 | — | 2,772 |
| Andrew Obenshain | Option | 186 | 36.78 | — |
| Andrew Obenshain | Option | 4,756 | 26.45 | — |
| Andrew Obenshain | Option | 16,331 | 14.17 | — |
| Andrew Obenshain | Option | 160,888 | 12.76 | — |
| Andrew Obenshain | Option | 48,750 | 7.8 | — |
| Andrew Obenshain | Option | 338,000 | 5.11 | — |
| Thomas Klima | Option | 35,573 | 15.5 | — |
| Thomas Klima | Option | 15,126 | 6.55 | — |
| Richard Colvin | Option | 2,195 | 14.17 | — |
| Thomas Klima | RSU | 8,250 | — | 11,385 |
| Thomas Klima | RSU | 25,096 | — | 34,632 |
| Richard Colvin | Option | 124 | 36.78 | — |
| Richard Colvin | Option | 110,000 | 5.11 | — |
| Thomas Klima | Option | 110,000 | 5.11 | — |
| Andrew Obenshain | RSU | 67,600 | — | 93,288 |
| Andrew Obenshain | RSU | 13,500 | — | 18,630 |
| Thomas Klima | Option | 27,090 | 7.8 | — |
| Richard Colvin | RSU | 9,975 | — | 13,766 |
| Richard Colvin | Option | 12,580 | 14.99 | — |
| Richard Colvin | Option | 14,300 | 7.8 | — |
bluebird bio's compensation program is designed to align executive interests with the drivers of growth and stockholder returns by supporting the Company's achievement of its primary business goals, while attracting and retaining employees whose talents and contributions are expected to sustain growth and drive long-term stockholder value. The Compensation Committee maintains an ongoing commitment to corporate governance principles and strong performance orientation, regularly reviewing compensation policies to ensure they are aligned with stockholder interests, business goals, and that total compensation is fair, reasonable, and competitive.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon plc (Human Capital Solutions practice) |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Mark VachonIndependent · Board Chair · Audit · Compensation (Chair) | $104,500 | $41,110 | $55,296 | — | $0 | $200,906 |
| Elisabeth LeidermanIndependent · Audit (Chair) · Compensation | 71,500 | 41,110 | 55,296 | — | 0 | 167,906 |
| John O. AgwunobiIndependent · Audit · Nominating/Governance (Chair) | 64,500 | 41,110 | 55,296 | — | 0 | 160,906 |
| Najoh Tita-ReidIndependent · Compensation · Nominating/Governance | 57,500 | 41,110 | 55,296 | — | 0 | 153,906 |
| Charlotte Jones-BurtonIndependent · Nominating/Governance | 50,000 | 41,110 | 55,296 | — | 0 | 146,406 |
| Nick LeschlyIndependent | — | 41,110 | 55,296 | — | 0 | 96,406 |
| Richard PaulsonIndependent · Newly elected | 33,500 | 15,388 | 16,350 | — | 0 | 65,238 |
| Andrew ObenshainEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Michael CloonanIndependent · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 15,000 / 10,000 |
| Stock ownership guideline | 3x annual cash retainer for non-employee directors; 3x base salary for CEO |
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $381,500 |
| Equity awards (grant-date value) | $262,048 |
| All other compensation | $0 |
| Total cost of the board | $643,548 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | bluebird bio | 2023 | Andrew Obenshain | $681,657 | $863,590 | $1,142,440 | $348,024 | $3,049,181 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Andrew Obenshain | DEF 14A | 2024-09-26 | 0001293971-24-000049 | Section “Summary Compensation Table”. As printed: 3,049,181. Filing ↗machine: r2 · c21 · span 402787–402796 |
| 2 | Section 01, Richard Colvin | DEF 14A | 2024-09-26 | 0001293971-24-000049 | Section “Summary Compensation Table”. As printed: 1,344,253. Filing ↗machine: r6 · c21 · span 409492–409501 |
| 3 | Section 01, Thomas Klima | DEF 14A | 2024-09-26 | 0001293971-24-000049 | Section “Summary Compensation Table”. As printed: 1,329,535. Filing ↗machine: r4 · c21 · span 406139–406148 |
| 4 | Section 03, Andrew Obenshain PRSU | DEF 14A | 2024-09-26 | 0001293971-24-000049 | Section “EXECUTIVE OFFICER AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t28 · r2 · c4 · span 402101–402108 |
| 5 | Section 03, Thomas Klima Option | DEF 14A | 2024-09-26 | 0001293971-24-000049 | Section “EXECUTIVE OFFICER AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t28 · r4 · c3 · span 405328–405335 |
| 6 | Section 03, Andrew Obenshain Option | DEF 14A | 2024-09-26 | 0001293971-24-000049 | Section “EXECUTIVE OFFICER AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t28 · r2 · c3 · span 401870–401879 |
| 7 | Section 03, Richard Colvin Option | DEF 14A | 2024-09-26 | 0001293971-24-000049 | Section “EXECUTIVE OFFICER AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t28 · r6 · c3 · span 408681–408688 |
| 8 | Section 03, Thomas Klima PRSU | DEF 14A | 2024-09-26 | 0001293971-24-000049 | Section “EXECUTIVE OFFICER AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t28 · r4 · c4 · span 405531–405538 |
| 9 | Section 03, Richard Colvin PRSU | DEF 14A | 2024-09-26 | 0001293971-24-000049 | Section “EXECUTIVE OFFICER AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t28 · r6 · c4 · span 408884–408891 |
| 10 | Section 08, Mark Vachon | DEF 14A | 2024-09-26 | 0001293971-24-000049 | Section “Director Compensation”. As printed: 200,906. Filing ↗machine: t37 · r3 · c10 · span 565722–565932 |
| 11 | Section 08, Elisabeth Leiderman | DEF 14A | 2024-09-26 | 0001293971-24-000049 | Section “Director Compensation”. As printed: 167,906. Filing ↗machine: span 567165–567375 |
| 12 | Section 08, John O. Agwunobi | DEF 14A | 2024-09-26 | 0001293971-24-000049 | Section “Director Compensation”. As printed: 160,906. Filing ↗machine: span 564240–564476 |
| 13 | Section 08, Najoh Tita-Reid | DEF 14A | 2024-09-26 | 0001293971-24-000049 | Section “Director Compensation”. As printed: 153,906. Filing ↗machine: t37 · r5 · c10 · span 568598–568808 |
| 14 | Section 08, Charlotte Jones-Burton | DEF 14A | 2024-09-26 | 0001293971-24-000049 | Section “Director Compensation”. As printed: 146,406. Filing ↗machine: span 570051–570261 |
| 15 | Section 08, Nick Leschly | DEF 14A | 2024-09-26 | 0001293971-24-000049 | Section “Director Compensation”. As printed: 96,406. Filing ↗machine: t37 · r8 · c10 · span 573081–573290 |
| 16 | Section 08, Richard Paulson | DEF 14A | 2024-09-26 | 0001293971-24-000049 | Section “Director Compensation”. As printed: 65,238. Filing ↗machine: t37 · r7 · c10 · span 571488–571697 |
| 17 | Section 08, Andrew Obenshain | DEF 14A | 2024-09-26 | 0001293971-24-000049 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 18 | Section 08, Michael Cloonan | DEF 14A | 2024-09-26 | 0001293971-24-000049 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 19 | Section 02, Andrew Obenshain 2025-01-06 | Form 4 | 2025-01-08 | 0001562180-25-000269 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Richard Colvin 2025-01-06 | Form 4 | 2025-01-08 | 0001562180-25-000270 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Joseph Vittiglio 2025-02-03 | Form 4 | 2025-02-05 | 0001562180-25-000951 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Richard Colvin 2025-02-03 | Form 4 | 2025-02-05 | 0001562180-25-000952 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Andrew Obenshain 2025-02-03 | Form 4 | 2025-02-05 | 0001562180-25-000950 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Thomas Klima 2025-02-03 | Form 4 | 2025-02-05 | 0001562180-25-000953 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Andrew Obenshain 2025-02-10 | Form 4 | 2025-02-12 | 0001562180-25-001152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Richard Colvin 2025-03-03 | Form 4 | 2025-03-05 | 0001562180-25-002090 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Andrew Obenshain 2025-03-03 | Form 4 | 2025-03-05 | 0001562180-25-002088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Thomas Klima 2025-03-03 | Form 4 | 2025-03-05 | 0001562180-25-002089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Nick Leschly 2025-05-30 | Form 4 | 2025-06-03 | 0000950170-25-081115 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Thomas Klima 2025-05-30 | Form 4 | 2025-06-03 | 0000950170-25-081125 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Najoh Tita-Reid 2025-05-30 | Form 4 | 2025-06-03 | 0000950170-25-081150 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Mark Vachon 2025-05-30 | Form 4 | 2025-06-03 | 0000950170-25-081156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Charlotte Jones-Burton 2025-05-30 | Form 4 | 2025-06-03 | 0000950170-25-081131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Elisabeth Leiderman 2025-05-30 | Form 4 | 2025-06-03 | 0000950170-25-081135 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Richard Colvin 2025-05-30 | Form 4 | 2025-06-03 | 0000950170-25-081151 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Richard Paulson 2025-05-30 | Form 4 | 2025-06-03 | 0000950170-25-081108 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Joseph Vittiglio 2025-05-30 | Form 4 | 2025-06-03 | 0000950170-25-081175 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Andrew Obenshain 2025-05-30 | Form 4 | 2025-06-03 | 0000950170-25-081140 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Nick Leschly 2025-05-30 | Form 4 | 2025-06-03 | 0000950170-25-081115 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Nick Leschly 2025-05-30 | Form 4 | 2025-06-03 | 0000950170-25-081115 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, John O. Agwunobi 2025-05-30 | Form 4 | 2025-06-03 | 0000950170-25-081163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, O. James Sterling 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081123 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Richard Colvin 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081151 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Joseph Vittiglio 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081175 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Thomas Klima 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081125 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Thomas Klima 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081125 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Andrew Obenshain 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081140 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, O. James Sterling 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081123 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Thomas Klima 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081125 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Mark Vachon 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, John O. Agwunobi 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Joseph Vittiglio 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081175 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Joseph Vittiglio 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081175 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Michael Cloonan 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, O. James Sterling 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081123 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Elisabeth Leiderman 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081135 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Najoh Tita-Reid 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081150 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Charlotte Jones-Burton 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Andrew Obenshain 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081140 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Andrew Obenshain 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081140 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Richard Colvin 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081151 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Richard Paulson 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081108 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Richard Colvin 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081151 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Nick Leschly 2025-06-02 | Form 4 | 2025-06-03 | 0000950170-25-081115 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 66 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 67 | Section 09b board cost (computed) | Computed | — | — | Cash 381,500 + equity 262,048 + all other 0 = 643,548, summed across the director compensation table rows.machine: formula: Σ = 643,548 |
| 68 | bluebird bio (subject), Section 10b CEO total | DEF 14A | 2024-09-26 | 0001293971-24-000049 | CEO total compensation as printed in bluebird bio's own proxy. As printed: 3,049,181. Filing ↗machine: r2 · c21 · span 402787–402796 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.